Skip to main content
OpenTrials
Completed

NCT Number: NCT04348799

Thrombocytopoiesis and Platelet Homeostasis in Infants With Bronchoplumonary Dysplasia

To investigate the relationship between bronchopulmonary dysplasia and thrombocytopenia.

Completed

Looking for future studies?

Notify Me

Key information

About this study

A prosepective case-control study ,the case were matched with 1:1according to gestational age,birth weight and admission diagnosis and divided into two groups according to the consensus definition of National Institute of Child Health and Human Development (NICHD). Platelet count, circulating megakaryocyte count, platelet activating markers (CD62P and CD63), thrombopoietin were recorded and compared in two groups, then, serial thrombopoietin levels and concomitant platelet counts were measured in infants with BPD.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • presence of clinical and radiologic signs of BPD, according to conventional criteria (Greenough, 1992);
  • presence of peripheral arterial catheter;
  • gestation <32 weeks;
  • birth weight <1.5 kg;
  • requiring mechanical ventilation for the treatment of respiratory distress syndrome for at least 3 days during the first weeks of life;
  • ventilator and/or oxygen dependent at time of enrolment;

Exclusion criteria

  • congenital abnormalities;
  • infection (bacteria infection confirmed by positive blood culture or viral infection confirmed by serological test or viral culture)
  • evidence of complications of perinatal asphyxia including an apgar score <3 at one or five minute after birth, evidence of hypoxic-ischemic encephalopathy, acute tubular necrosis, or transient myocardial ischemia;
  • identifiable hematologic disease;

Treatment and study plan

BPD

Other

It is a observation research.we didn't intervene anything.

Primary outcomes

  1. Platelet counts and Circulating MK counts

    Time frame: up to 4 weeks

    Platelet counts and Circulating MK counts

Secondary outcomes

  1. CD62P and CD63 expression

    Time frame: up to 4 weeks

    CD62P and CD63 expression

  2. TPO

    Time frame: up to 4 weeks

    Plasma TPO concentration

  3. TPO and platelet

    Time frame: up to 6 weeks

    the relationship betweenTPO concentration and Platelet counts in BPD with thrombocytopenia

Sponsors and collaborators

Lead sponsor

yangjie

Other

Registry information

Acronym: BPD

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Apr 16, 2020
Registry last updated
Apr 16, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.